TUMORIGENICITY OF VERO CELLS
TUMORIGENICITY OF VERO CELLS
复制标题
DOI：
10.1016/s0092-1157(84)80063-3
复制
发表时间：
1984-01-01
期刊：
影响因子：
--
通讯作者：
ELISBERG, BL
中科院分区：
文献类型：
--
作者：
LEVENBOOK, IS;PETRICCIANI, JC;ELISBERG, BL
目前评估用于疫苗生产的细胞系可接受性的标准之一是缺乏致瘤性。Vero细胞代表了一类称为连续细胞系的细胞。它们来自非洲绿猴肾；与用于疫苗生产的其他细胞底物相比，它们的生长特性和培养特性具有许多优势。Vero细胞在裸鼠和人类肌肉器官培养系统中进行了致瘤性测试，发现随着传代次数的增加，其致瘤潜力显著增加。传代在232代及以上的细胞在所有接种的裸鼠中都能产生结节。组织学上，这些结节是界限清楚的间变性肿瘤，表现出肾腺癌的一些特征。约6~8天后，所有结节均开始消退。显然，一种免疫机制是这种退化现象的基础。
One of the current criteria for evaluating the acceptability of cell lines for use in vaccine production is lack of tumorigenicity. Vero cells represent an example of a class of cells known as continuous cell lines. They were derived from African green monkey kidney; their growth properties and culture characteristics have many advantages over other cell substrates for use in vaccine production. Vero cells were tested for tumorigenicity in nude mice and in a human muscle organ culture system, and a significant increase in their tumorigenic potential with increasing passage numbers was found. Cells at passage 232 and higher produced nodules in all nude mice inoculated. Histologically the nodules were well defined, anaplastic tumors, which exhibited some of the characteristics of renal adenocarcinomas. In about 6 to 8 days all of the nodules began to regress. An immune mechanism apparently, was the basis for the regression phenomenon.